Avalo Therapeutics (AVTX) Short term Debt (2014 - 2019)

Avalo Therapeutics' Short term Debt history runs 6 years deep, the most recent figure standing at $1.2 million for Q3 2019.

• Quarterly Short term Debt fell 36.8% year-over-year to $1.2 million in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $1.2 million (down 36.8% YoY) and the FY2018 annual result came in at $859670.0, changed N/A from the prior year.
• Short term Debt was $1.2 million for Q3 2019 at Avalo Therapeutics, down from $1.5 million in the prior quarter.
• Across five years, Short term Debt topped out at $3.4 million in Q2 2016 and bottomed at $607598.0 in Q2 2017.
• A 5-year average of $2.0 million and a median of $2.0 million in 2018 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2017 — Short term Debt tumbled 82.08% — and 2019, when it surged 165.98%.
• Avalo Therapeutics' Short term Debt stood at $3.2 million in 2015, then dropped by 26.63% to $2.4 million in 2016, then plunged by 74.19% to $607598.0 in 2017, then soared by 41.49% to $859670.0 in 2018, then jumped by 43.94% to $1.2 million in 2019.
• Business Quant data shows AVTX's Short term Debt at $1.2 million in Q3 2019, $1.5 million in Q2 2019, and $2.2 million in Q1 2019.